Risk factor
Resilient to price shocks
Profitability factor
Very strong margins and returns
About
Universal Vision Biotechnology Co., Ltd., established in 1992 and based in Taipei, Taiwan, manages a network of eye care clinics across both Taiwan and China. The company delivers a comprehensive range of ophthalmic services, encompassing advanced surgical interventions and treatments for various ocular conditions. Its surgical specialties include laser vision correction for common refractive errors such as myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related vision decline). They also perform intraocular lens procedures for presbyopia and cataracts, employing advanced techniques like phacoemulsification and femtosecond laser surgery. Beyond surgical solutions, Universal Vision addresses a wide spectrum of eye health concerns, offering services for myopia control, dry eye syndrome, retinal detachment, macular degeneration, strabismus (crossed eyes), amblyopia (lazy eye), and numerous other ophthalmic ailments. The company further provides a diverse array of vision products and optical aids, including various eyeglass frames, specialized multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, and both conventional and colored contact lenses. Nutritional eye supplements are also available. Additional offerings include oculoplastic and micro cosmetic eye surgery, alongside bespoke aesthetic medicine consultations. Furthermore, Universal Vision engages in optometric services, hospital administration, technical advisory roles, and the distribution and rental of medical equipment.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, unde
Target Price
The average target price of 3218.TWO is 150 and suggests 10.3% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda